Brain wave study hints at new Drug's potential
NCT ID NCT05049343
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage study tested a drug called SAGE-904 in 22 healthy volunteers to see how it changes brain activity after a ketamine challenge. Researchers measured brain waves using EEG to check if SAGE-904 alters responses to sounds. The goal was to understand how the drug works in the brain, not to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SAGE-904
- What this could lead to
- If successful, this study could help researchers understand how SAGE-904 affects brain activity, potentially guiding future studies for conditions like depression or schizophrenia.
- What could go wrong
- This is a very early Phase 1 study in only 22 healthy people, not patients. It measures brain signals, not symptoms, so even positive results may not lead to a treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sage Investigational Site
Newark, New Jersey, 07103, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can eye movements reveal the Brain's visual priorities?
- A new eye on the brain: could this tracer unlock Addiction's secrets?
- First look: can a new drug candidate pass early safety tests in humans?
- A painless, contact-free vibration sensor may detect hidden heart and lung problems
- Can a Two-Pathway pill improve ED treatment? a new trial puts the combo to the test
- Could a common drug shield the brain from Alzheimer's?